Coexistence of iAMP21 and ETV6-RUNX1 fusion in an adolescent with B cell acute lymphoblastic leukemia: literature review of six additional cases

Table 1 Clinical and laboratory data of the patient

Date	10/9/2013	6/24/2014	12/9/2014	12/31/2014	6/8/2015	8/19/2015
Significant event	Initial diagnosis	MRD Positive	1^st Relapse	Persistent disease	Post-ASCT^a	2^nd Relapse
BM Blast (%) (0–5)	61	NA	5	54	1	25
WBC (x10⁹/L)	2.0	5.5	4.6	2.8	5.6	2.2
PLT (x10³/μL)	88	383	202	79	133	79
HB (g/dL)	8.3	10.8	13.3	12.9	9.1	11.4
Flow-cytometry analysis	Positive^b	Positive	Positive^c	Positive^d	NA	Positive
G-Band karyotyping	NA^e	NA	46,XY	Complex	46,XY	46,XY
ETV6-RUNX1/iAMP21 FISH	Positive	Negative	Borderline Negative	Positive	NA	NA
ETV6-RUNX1 by PCR	NA	NA	NA	Positive	NA	NA
Treatment	CALGB^f	Post- CALGB	Blinatumomab	Hyper-CVAD^g + Inotuzumab	50 days Post-ASCT	EPOCH^h + Rituxan

^a Post ASCT post allogeneic stem cell transplantation
^bCD19lo, CD22+, cytoplasmic CD79a+, HLA-DR+, aberrant CD13 and CD33 expression, CD3-, CD10-, CD20-, surface Ig-, CD34-, CD38-,MPO-
^cCD10+, CD13+, CD19lo, CD33+/lo, CD9-, CD20-, CD34-, surface Ig-
^dCD10+, CD13+, CD19+, CD22+,CD33+ (subset), CD45 dim, CD38 dim, CD58, cytoplasmic CD79a, CD81, TdT+, cytoplasmic CD3-, CD15-, CD20-, CD25-, CD34-, CD66c-, CD117-, CRLF2-, cytoplasmic IgM-, MPO-
^e NA not available
^fCALGB: IT Cytarabine, Daunorubicin, Vincristine, IT Methotrexate, PEG Asparaginase and Prednisone
^gHyper-CVAD: Cyclophosphamide, Vincristine, Doxorubicin Hydrochloride, Dexamethasone
^hEPOCH: Etoposide, Vincristine, Cyclophosphamide, Doxorubicin Hydrochloride

ISSN: 1755-8166